Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development.

Jes Dietrich, T Mark Doherty

Journal: APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2009;117(5-6):440-57

PMID: 19400867

Abstract

Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), remains a major worldwide health problem that causes more than 2 million deaths annually. In addition, an estimated 2 billion people are latently infected with M. tuberculosis. The bacterium is one of the oldest human pathogens and has evolved complex strategies for survival. Therefore, to be successful in the high endemic regions, any future TB vaccine strategy will have to be tailored in accordance with the resulting complexity of the TB infection and anti-mycobacterial immune response. In this review, we will discuss what is presently known about the interaction of M. tuberculosis with the immune system, and how this knowledge is used in new and more advanced vaccine strategies.

Address: Department of Infectious Disease Immunology, Statens Serum Institute, Copenhagen, Denmark. [email protected]

DOI: 10.1111/j.1600-0463.2009.02458.x

Link outs

Free resources

Medical:

https://medlineplus.gov/tuberculosis.html

Subscription / membership required

Full Text Sources:

https://doi.org/10.1111/j.1600-0463.2009.02458.x

MeSH Terms: Adult, Antitubercular Agents, Apoptosis, BCG Vaccine, Clinical Trials, Phase II as Topic, Drug Design, Global Health, Host-Pathogen Interactions, Humans, Interferon-gamma, Interleukins, Macrophage Activation, Macrophages, Mycobacterium tuberculosis, Phagocytosis, Receptors, Pattern Recognition, Tuberculosis, Tuberculosis Vaccines, Vaccines, Subunit, Vaccines, Synthetic